Crisaborole

Generic Name: Crisaborole

Brand Names: Eucrisa

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₀BNO_₃

CAS Number: 906673-24-3

Unique Ingredient Identifier: Q2R47HGR7P

Background: Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.

This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile. Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme. It is currently under development as topical treatment of psoriasis.

Indication: Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.

Associated Conditions: Mild Atopic dermatitis, Moderate Atopic dermatitis

Clinical Trials

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

Phase 2

Completed

Conditions: Stasis Dermatitis

Interventions: Drug: crisaborole ointment
Other: vehicle ointment

First Posted Date: 2019-09-16

Last Posted Date: 2022-05-02

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT04091087

Locations: 🇺🇸
Hawthorne Effect, Inc, Lafayette, California, United States
🇺🇸
Lightship, El Segundo, California, United States
🇺🇸
Onco360 Oncology Pharmacy, Louisville, Kentucky, United States

and more 1 locations

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Crisaborole 2%
Drug: Vehicle

First Posted Date: 2019-07-31

Last Posted Date: 2023-03-08

Lead Sponsor: Pfizer

Target Recruit Count: 620

Registration Number: NCT04040192

Locations: 🇺🇸
Skin Care Research LLC, Boca Raton, Florida, United States
🇮🇱
The Chaim Sheba Medical Center, Ramat - Gan, Israel
🇺🇸
Colorado Springs Dermatology Clinic, PC, Colorado Springs, Colorado, United States

and more 40 locations

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Phase 4

Completed

Conditions: Atopic Dermatitis
Eczema

Interventions: Drug: Crisaborole

First Posted Date: 2019-07-17

Last Posted Date: 2022-07-19

Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

Target Recruit Count: 30

Registration Number: NCT04023084

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Crisaborole 2% Topical Application Ointment [EUCRISA]
Drug: Triamcinolone Acetonide 0.1% Ointment

First Posted Date: 2019-07-05

Last Posted Date: 2021-04-28

Lead Sponsor: Clinical Research Center of the Carolinas

Target Recruit Count: 16

Registration Number: NCT04008784

Locations: 🇺🇸
Clinical Research Center of the Carolinas, Charleston, South Carolina, United States

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Crisaborole ointment 2%
Drug: Vehicle

First Posted Date: 2019-05-17

Last Posted Date: 2020-07-14

Lead Sponsor: Pfizer

Target Recruit Count: 81

Registration Number: NCT03954158

Locations: 🇯🇵
Fukuwa Clinic, Chuo-ku, Tokyo, Japan
🇯🇵
Sekino Hospital, Toshima-ku, Tokyo, Japan
🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan